#153288

phOC-iNOS Vector

Cat. #153288

phOC-iNOS Vector

Cat. #: 153288

Sub-type: pcDNA 3.1

Availability: 3-5 days

Target: Inducible Nitric Oxide Synthase

Bacterial Resistance: Kanamycin

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Helen McCarthy

Institute: Queen's University Belfast

Tool Details
Handling
Target Details
Application Details
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: phOC-iNOS Vector
  • Alternate name: Nitric Oxide Synthase
  • Research fields: Cancer;Metabolism;Neurobiology
  • Tool sub type: pcDNA 3.1
  • Bacterial resistance: Kanamycin
  • Description: phOC-iNOS Plasmid is a human nitric oxide synthase (iNOS) transgene driven by a human osteocalcin (hOC) promoter to control inducible nitric oxide synthase (iNOS) transgene expression in hormone refractory prostate cancer (HRPC). The plasmid was originally developed as an anti-cancer therapeutic with a view to a gene therapy strategies. Studies in the literature have demonstrated that this plasmid increases iNOS protein and total nitrite levels in PC3 and DU145 cells, but not LNCaP or HT29 (McCarthy et al., 2007). The plasmid serves as a useful tool in cardiovascular studies or any physiology associated with vasodilation.

Handling

  • Storage conditions: -80° C
  • Shipping conditions: Dry Ice

Target Details

  • Target: Inducible Nitric Oxide Synthase

Application Details

  • Application notes: Recommended for transpormation in DH5 alpha bacterial cells iNOS gene is 4.4kb

Related Tools

  • Related tools: pCMV-iNOS Vector

References

  • McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.
  • Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.